Inhaled corticosteroids can reduce osteoporosis in female patients with COPD

• Published in: International journal of chronic obstructive pulmonary disease 2016-01, Vol.11 (1), p.1607-1614
• Main Authors: Liu, Shih-Feng, Kuo, Ho-Chang, Liu, Guan-Heng, Ho, Shu-Chen, Chang, Huang-Chih, Huang, Hung-Tu, Chen, Yu-Mu, Huang, Kuo-Tung, Chen, Kuan-Yi, Fang, Wen-Feng, Lin, Meng-Chih
• Format: Article
• Language: English
• Subjects: Administration, Inhalation; Adrenal Cortex Hormones - administration & dosage; Adult; Age Factors; Asthma; Bone density; Bronchodilator Agents - administration & dosage; Chronic obstructive lung disease; Chronic obstructive pulmonary disease; Comorbidity; Corticosteroid drugs; Databases, Factual; Development and progression; Dose-Response Relationship, Drug; Drug dosages; Female; Females; Health insurance; Health services; Humans; Incidence; Lung - drug effects; Lung - physiopathology; Males; Medical research; Metabolism; Middle Aged; National health insurance; Original Research; Osteoporosis; Osteoporosis - diagnosis; Osteoporosis - epidemiology; Osteoporosis - prevention & control; Patients; Population; Proportional Hazards Models; Protective Factors; Pulmonary Disease, Chronic Obstructive - diagnosis; Pulmonary Disease, Chronic Obstructive - drug therapy; Pulmonary Disease, Chronic Obstructive - epidemiology; Pulmonary Disease, Chronic Obstructive - physiopathology; Reimbursement; Retrospective Studies; Risk Factors; Sex Factors; Smoking; Steroids; Taiwan - epidemiology; Time Factors; Tobacco; Treatment Outcome; Women's health
• ISSN: 1178-2005; 1176-9106; 1178-2005
• DOI: 10.2147/COPD.S106054

Whether the use of inhaled corticosteroids (ICSs) in patients with COPD can protect from osteoporosis remains undetermined. The aim of this study is to assess the incidence of osteoporosis in patients with COPD with ICS use and without. This is a retrospective cohort and population-based study in which we extracted newly diagnosed female patients with COPD between 1997 and 2009 from Taiwan's National Health Insurance (TNHI) database between 1996 and 2011 (International Classification of Diseases, Ninth Revision - Clinical Modification [ICD-9-CM] 491, 492, 496). The patients with COPD were defined by the presence of two or more diagnostic codes for COPD within 12 months on either inpatient or outpatient service claims submitted to TNHI. Patients were excluded if they were younger than 40 years or if osteoporosis had been diagnosed prior to the diagnosis of COPD and cases of asthma (ICD-9 CM code 493.X) before the index date. These enrolled patients were followed up till 2011, and the incidence of osteoporosis was determined. The Cox proportional hazards regression model was also used to estimate hazard ratios (HRs) for incidences of lung cancer. Totally, 10,723 patients with COPD, including ICS users (n=812) and nonusers (n=9,911), were enrolled. The incidence rate of osteoporosis per 100,000 person years is 4,395 in nonusers and 2,709 in ICS users (HR: 0.73, 95% confidence interval [CI]: 0.63-084). The higher ICS dose is associated with lower risk of osteoporosis (0 mg to ≤20 mg, HR: 0.84, 95% CI: 0.69-1.04; >20 mg to ≤60 mg, HR: 0.78, 95% CI: 0.59-1.04; and >60 mg, HR: 0.72, 95% CI: 0.55-0.96; P for trend =0.0023) after adjusting for age, income, and medications. The cumulative osteoporosis probability significantly decreased among the ICS users when compared with the nonusers (P